Study of E7386 in Participants With Selected Advanced Neoplasms

Summary

This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386.

Timeline

Start

2017-07-27

Primary completion

2027-03-31

Completion

2027-03-31

Publications

• Evans TRJ, Cook N, El-Khoueiry A, Pinato DJ, Tran NH, Hsiehchen D, Mena E, Meyer T, Wu J, Pathak SM, Paoletti C, Dutta L, Okpara CE, Lopez JS. A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms. Br J Cancer. 2026 Jun 4. doi: 10.1038/s41416-026-03488-w. Online ahead of print.

Drugs

Indications